Somatropin pegol LA is under clinical development by Changchun GeneScience Pharmaceutical and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Somatropin pegol LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Somatropin pegol LA overview

Somatropin pegol is a pegylated somatropin (Gensci-004/Jintrolong) acts as human growth hormone is a long acting recombinant human growth hormone. It is formulated as powder for solution for subcutaneous route of administration. Jintrolong is indicated for pediatric growth retardation due to inadequate secretion of endogenous growth hormone.

It is under development for the treatment of pituitary stalk interruption syndrome, non-alcoholic fatty liver disease (NAFLD), idiopathic short stature, X-linked dominant hypophosphatemic rickets, growth hormone deficiency and Turner syndrome. The drug candidate is developed using E.coli secretion technology which produces the human growth hormone protein of 191 amino acid residues. It was also under development for born small for gestational age.

Changchun GeneScience Pharmaceutical overview

GeneScience Pharmaceuticals Co Ltd (GeneScience), a subsidiary of Changchun High-tech Industrial (Group) Co Ltd, provides genetically engineered pharmaceutical products. The company offers products in various therapeutic areas such as assisted reproduction, growth and development, tumor, immune, antiviral and metabolic diseases. It offers child health science, wound healing and women health products. GeneScience sells its products under the brand names JINTROLONG, JINTROPIN, GENFULIN and JINFOLLIN. The company operates a marketing office in Shanghai, and research and development centers in Changchun, Shanghai and Beijing, China. GeneScience Pharmaceuticals is headquartered in Changchun, Jilin, China.

For a complete picture of Somatropin pegol LA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.